Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study

Abstract

The benefit from nintedanib was reduced in patients in Severe Group when compared to those in Mild to Moderate Group; however, the prognosis is expected to improve with control of side effects and long-term administration. It is more important to control the side effects in Severe Group.